Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences — Collaboration revenue by Quarter
Alpine Immune Sciences — Collaboration revenue ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences — Collaboration revenue: $7.03M in Q1 2024, down 25.1% from a year earlier. No newer figure appears in the documents we track.
Where the Q1 2024 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Collaboration revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2024 | Mar 31, 2024 | 7.03 | -25.1% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 30.9 | +1,014.1% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 10.0 | +20.0% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 8.59 | +62.4% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 9.39 | -31.1% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 2.77 | -38.9% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 8.37 | -1.8% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 5.29 | -26.4% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 13.6 | +325.9% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 4.53 | -19.7% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 8.52 | +346.1% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 7.19 | +942.0% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 3.20 | +193.6% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 5.64 | +540.9% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 1.91 | +558.6% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 0.69 | +21.1% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 1.09 | – | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 0.88 | -8,900.0% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 0.29 | – | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 0.57 | +46.2% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 0 | -100.0% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | -0.01 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 0 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 0.39 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | 0.32 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Collaboration revenue ($M), quarterly Q1 2018–Q1 2024 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-rev
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.